(Q39847061)

15 September 2017

1 reference

title

Glipizide: a second-generation sulfonylurea hypoglycemic agent. Pharmacology, pharmacokinetics and clinical use. (English)

1 reference

15 September 2017

1 reference

ChEBI release 2020-05-28

1 reference

1 reference

Lebovitz HE

1

1 reference

PubMed ID

3923454

15 September 2017

language of work or name

English

0 references

publication date

1 March 1985

1 reference

15 September 2017

1 reference

15 September 2017

5

1 reference

15 September 2017

63-77

1 reference

15 September 2017

2

1 reference

Glipizide: a review of its pharmacological properties and therapeutic use.

15 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03405.X

Specific receptors for sulfonylureas in brain and in a B-cell tumor of the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03405.X

Biosynthesis of proinsulin and insulin in newborn rat pancreas. Interaction of glucose, cyclic AMP, somatostatin, and sulfonylureas on the (3H) leucine incorporation into immunoreactive insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03405.X

Influence of food intake on the absorption and effect of glipizide in diabetics and in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03405.X

Impaired effect of sulfonylurea following increased dosage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03405.X

Long-term safety and efficacy of glipizide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03405.X

Selective potentiation of insulin-mediated glucose disposal in normal dogs by the sulfonylurea glipizide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03405.X

Effect of sulfonylurea treatment on in vivo insulin secretion and action in patients with non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03405.X

Mechanism of action of the second-generation sulfonylurea glipizide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03405.X

Interaction of glipizide with human serum albumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03405.X

Glipizide in the treatment of maturity-onset diabetes: a multi-centre, out-patient study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03405.X

21 January 2018

Glipizide: An overview

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03405.X

Glipizide versus tolbutamide, an open trial. Effects on insulin secretory patterns and glucose concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03405.X

Drug-induced hypoglycemia. A review based on 473 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03405.X

Sulphonylureas increase the number of insulin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1985.TB03405.X

10.1002/J.1875-9114.1985.TB03405.X

21 January 2018

Identifiers

DOI

1 reference

15 September 2017

1 reference

PubMed ID

3923454